牛牛AI助理已提取核心訊息
Adimab, LLC, a Delaware-based limited liability company, has filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission (SEC), reporting a significant transaction involving shares of Invivyd, Inc. The amendment, dated January 19, 2024, indicates that Adimab, LLC has sold 5,000,000 shares of Invivyd's common stock. The sale was executed under Rule 144 at a price of $3.95 per share. Following the sale, Adimab, LLC still beneficially owns 21,687,906 shares, representing 19.7% of Invivyd's class of common stock. This ownership percentage is based on the 110,114,960 shares of common stock outstanding as reported in Invivyd's Quarterly Report for the quarter ended September 30, 2023. The amendment also notes that the company, formerly known as Adagio Therapeutics, Inc., officially changed its name to Invivyd, Inc. on September 13, 2022, following the filing of a certificate of amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware. No other transactions in Invivyd's common stock were reported by Adimab, LLC or related persons in the past 60 days.
Adimab, LLC, a Delaware-based limited liability company, has filed an amendment to its Schedule 13D with the U.S. Securities and Exchange Commission (SEC), reporting a significant transaction involving shares of Invivyd, Inc. The amendment, dated January 19, 2024, indicates that Adimab, LLC has sold 5,000,000 shares of Invivyd's common stock. The sale was executed under Rule 144 at a price of $3.95 per share. Following the sale, Adimab, LLC still beneficially owns 21,687,906 shares, representing 19.7% of Invivyd's class of common stock. This ownership percentage is based on the 110,114,960 shares of common stock outstanding as reported in Invivyd's Quarterly Report for the quarter ended September 30, 2023. The amendment also notes that the company, formerly known as Adagio Therapeutics, Inc., officially changed its name to Invivyd, Inc. on September 13, 2022, following the filing of a certificate of amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware. No other transactions in Invivyd's common stock were reported by Adimab, LLC or related persons in the past 60 days.
總部位於特拉華州的有限責任公司Adimab, LLC已向美國證券交易委員會（SEC）提交了其附表13D的修正案，報告了一筆涉及Invivyd, Inc.股票的重大交易。該修正案於2024年1月19日發佈，表明Adimab, LLC已出售了Invivyd的500萬股普通股。此次出售是根據規則144執行的，價格爲每股3.95美元。出售後，Adimab, LLC仍實益擁有21,687,906股股票，佔Invivyd普通股類別的19.7％。該所有權百分比基於Invivyd截至2023年9月30日的季度季度報告中公佈的110,114,960股已發行普通股。該修正案還指出，該公司前身爲Adagio Therapeutics, Inc.，在向特拉華州國務卿提交了經修訂和重述的公司註冊證書的修正證書後，於2022年9月13日正式更名爲Invivyd, Inc.。在過去的60天中，Adimab, LLC或關聯人員沒有報告Invivyd普通股的其他交易。
總部位於特拉華州的有限責任公司Adimab, LLC已向美國證券交易委員會（SEC）提交了其附表13D的修正案，報告了一筆涉及Invivyd, Inc.股票的重大交易。該修正案於2024年1月19日發佈，表明Adimab, LLC已出售了Invivyd的500萬股普通股。此次出售是根據規則144執行的，價格爲每股3.95美元。出售後，Adimab, LLC仍實益擁有21,687,906股股票，佔Invivyd普通股類別的19.7％。該所有權百分比基於Invivyd截至2023年9月30日的季度季度報告中公佈的110,114,960股已發行普通股。該修正案還指出，該公司前身爲Adagio Therapeutics, Inc.，在向特拉華州國務卿提交了經修訂和重述的公司註冊證書的修正證書後，於2022年9月13日正式更名爲Invivyd, Inc.。在過去的60天中，Adimab, LLC或關聯人員沒有報告Invivyd普通股的其他交易。
有用
沒用
